Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China.
Department of General Internal Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.
Cancer Immunol Immunother. 2023 Aug;72(8):2741-2755. doi: 10.1007/s00262-023-03446-y. Epub 2023 Apr 29.
Neoantigen vaccines constitute an emerging and promising cancer immunotherapy. However, not all neoantigens have anti-tumor activity, as poor CD4 epitope recognition can lead to the lack of greatly limit the persistence of the CD8 T cell response. Therefore, we designed a self-assembled nanoplatform hereinafter referred to as DNA-coupled nitrated T helper cell epitope nanoparticle (DCNP) based on DNA origami containing a nitrated CD4 + T cell epitope, which can facilitate the effective activation of neoantigen-specific CD8 T cells. Moreover, we embedded the cytidine-phosphate-guanosine oligonucleotide (CpG ODN) motif sequence in the DNA skeleton to function as a built-in adjuvant to activate Toll-like receptor 9. DCNP can markedly improve adjuvant and neoantigen co-delivery to lymphoid organs and promote neoantigen presentation on dendritic cells. Moreover, DCNP induced robust, and long-lived neoantigen-specific CD8 T cell responses that significantly delayed tumor growth. Further, these effects were largely dependent on the nitrated T cell epitope. Collectively, our findings indicate that DCNP is a promising platform that could improve the development of personalized therapeutic neoantigen vaccines for cancer immunotherapy.
基于 DNA 折纸的新型纳米载体,可有效激活针对新抗原的 CD8+T 细胞
新型抗原疫苗是一种新兴的、有前途的癌症免疫疗法。然而,并非所有的新型抗原都具有抗肿瘤活性,因为 CD4+表位识别不佳可能导致 CD8+T 细胞反应的持久性大大受限。因此,我们设计了一种自组装纳米平台,以下简称 DNA 偶联硝基 T 辅助细胞表位纳米颗粒(DCNP),该平台基于含有硝基 CD4+T 细胞表位的 DNA 折纸,可有效激活针对新抗原的 CD8+T 细胞。此外,我们在 DNA 骨架中嵌入了胞嘧啶-磷酸-鸟嘌呤寡核苷酸(CpG ODN)基序序列,作为一种内源性佐剂,激活 Toll 样受体 9。DCNP 可显著改善佐剂和新抗原向淋巴器官的共递呈,并促进树突状细胞对新抗原的呈递。此外,DCNP 诱导了强烈且持久的针对新抗原的 CD8+T 细胞反应,显著延缓了肿瘤生长。进一步的研究表明,这些效果在很大程度上依赖于硝基 T 细胞表位。总之,我们的研究结果表明,DCNP 是一种很有前途的平台,可用于改进癌症免疫治疗中个性化治疗性新抗原疫苗的开发。